HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients.

AbstractPURPOSE:
To examine the relationship between glucose transporter-1 (GLUT-1) and vascular endothelial growth factor (VEGF) expression and (18)F-FDG uptake in esophageal squamous cell cancer patients.
MATERIALS AND METHODS:
Fifty-seven patients (52 male and 5 female) were included in this study. (18)F-FDG PET/CT was performed prior to the surgery. Immunohistochemistry was performed using postoperative histopathological specimens. The estimation of immunohistochemistry was conducted using scoring analysis. We investigated the correlations between maximum standardized uptake value (SUV(max)) and GLUT-1/VEGF expressions/pathologic tumor length (p-tumor length), and the relationships between pathologic T (p-T) stage and GLUT-1/VEGF expressions/SUV(max) and between lymph node metastasis (p-N) stage and GLUT-1/VEGF expressions/SUV(max).
RESULTS:
SUV(max) significantly correlated with GLUT-1 expressions and p-tumor length (GLUT-1: r = 0.475, P < 0.001; p-tumor length: r = 0.475, P < 0.001). SUV(max) of the primary tumor had a significant relationship with p-T stage, p-N stage, and VEGF expression (p-T stage: P < 0.001; p-N stage: P = 0.037; VEGF expression: P = 0.009). There was a statistically significant difference between GLUT-1 expression and p-T stage/VEGF expression, but not p-N stage (p-T stage: P = 0.012; VEGF expression: P = 0.01; p-N stage: P = 0.572). VEGF expression had a significant relationship with p-T stage, but not with p-N stage (p-T stage: P = 0.032; p-N stage: P = 0.763).
CONCLUSION:
(18)F-FDG uptake can be determined by GLUT-1 and VEGF. SUV(max) would have a connection with the tumor progression and lymph node metastasis.
AuthorsMaiko Kobayashi, Hayato Kaida, Akihiko Kawahara, Satoshi Hattori, Seiji Kurata, Masanobu Hayakawa, Yasumitsu Hirose, Masafumi Uchida, Masayoshi Kage, Hiromasa Fujita, Naofumi Hayabuchi, Masatoshi Ishibashi
JournalClinical nuclear medicine (Clin Nucl Med) Vol. 37 Issue 5 Pg. 447-52 (May 2012) ISSN: 1536-0229 [Electronic] United States
PMID22475893 (Publication Type: Journal Article)
Chemical References
  • Glucose Transporter Type 1
  • SLC2A1 protein, human
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Fluorodeoxyglucose F18
Topics
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell (diagnostic imaging, metabolism, pathology)
  • Esophageal Neoplasms (diagnostic imaging, metabolism, pathology)
  • Female
  • Fluorodeoxyglucose F18 (pharmacokinetics)
  • Glucose Transporter Type 1 (metabolism)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radionuclide Imaging
  • Tumor Burden
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: